Home/Filings/4/0000899243-21-032748
4//SEC Filing

New Leaf Ventures III, L.P. 4

Accession 0000899243-21-032748

CIK 0001708493other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 4:15 PM ET

Size

17.5 KB

Accession

0000899243-21-032748

Insider Transaction Report

Form 4
Period: 2021-01-11
Transactions
  • Purchase

    Common Stock

    2021-01-11$17.00/sh+235,294$3,999,998913,860 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,839
Transactions
  • Purchase

    Common Stock

    2021-01-11$17.00/sh+235,294$3,999,998913,860 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,839
Transactions
  • Purchase

    Common Stock

    2021-01-11$17.00/sh+235,294$3,999,998913,860 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,839
Transactions
  • Purchase

    Common Stock

    2021-01-11$17.00/sh+235,294$3,999,998913,860 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,839
Transactions
  • Purchase

    Common Stock

    2021-01-11$17.00/sh+235,294$3,999,998913,860 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,839
Transactions
  • Purchase

    Common Stock

    2021-01-11$17.00/sh+235,294$3,999,998913,860 total(indirect: See footnote)
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,839
Footnotes (4)
  • [F1]These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. ("BPO-II"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. ("NLBA-II"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. ("BPO Management-II"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F2]Each of Ronald M. Hunt, a member of the Issuer's board of directors, and Vijay K. Lathi are the managers of BPO Management-II (the "BPO-II Managers") and may be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F3]These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III" and together with BPO-II, the "NLV Funds"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F4]Each of Ronald M. Hunt, a member of the Issuer's board of directors, and Vijay K. Lathi, are the managers of Management-III (the "NLV-III Managers") and may be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Issuer

Harpoon Therapeutics, Inc.

CIK 0001708493

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001625653

Filing Metadata

Form type
4
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 4:15 PM ET
Size
17.5 KB